Replimune Group (NASDAQ:REPL) Shares Gap Up – Still a Buy?

Replimune Group, Inc. (NASDAQ:REPL) shares gapped up before the market opened on Tuesday . The stock had previously closed at $13.26, but opened at $13.64. Replimune Group shares last traded at $14.15, with a volume of 561,791 shares.

Analyst Ratings Changes

A number of brokerages recently issued reports on REPL. Roth Mkm started coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $17.00 price target on shares of Replimune Group in a research note on Friday. JPMorgan Chase & Co. boosted their target price on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. BMO Capital Markets lifted their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $17.00.

Replimune Group Stock Performance

The stock’s 50-day moving average price is $11.64 and its 200-day moving average price is $9.81. The company has a market capitalization of $960.62 million, a price-to-earnings ratio of -4.37 and a beta of 1.19. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.07. As a group, equities research analysts expect that Replimune Group, Inc. will post -3.02 earnings per share for the current year.

Insider Activity

In other news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now directly owns 109,885 shares in the company, valued at $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

Several hedge funds and other institutional investors have recently bought and sold shares of REPL. Barclays PLC grew its position in shares of Replimune Group by 165.5% in the third quarter. Barclays PLC now owns 158,491 shares of the company’s stock valued at $1,738,000 after purchasing an additional 98,791 shares during the period. Geode Capital Management LLC grew its holdings in Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after buying an additional 217,308 shares during the period. State Street Corp lifted its holdings in shares of Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after acquiring an additional 1,182,181 shares during the period. Parkman Healthcare Partners LLC boosted its position in shares of Replimune Group by 45.5% in the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock worth $8,371,000 after acquiring an additional 238,747 shares during the last quarter. Finally, Arizona PSPRS Trust purchased a new stake in Replimune Group in the third quarter valued at approximately $834,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.